Insight

Jun Gong: ctDNA-guided adjuvant immunotherapy in stage III MSI-H dMMR colon cancer

Jun Gong/LinkedIn

Nov 19, 2024, 20:48

Jun Gong: ctDNA-guided adjuvant immunotherapy in stage III MSI-H dMMR colon cancer

Jun Gong, Medical Oncologist and Researcher at Cedars-Sinai Medical Center, shared a post on X about a recent paper by him and colleagues published in Taylor and Francis Research Insights’ Immunotherapy Journal.

“Just published! ctDNA-guided adjuvant immunotherapy in stage III MSI-H dMMR colon cancer following failure to clear MRD with adjuvant oxalipatin-based chemo.

Full access here.”

“ctDNA-guided adjuvant immunotherapy in colorectal cancer”

Authors: Nicholas Burley, Yurhee Lee, Louisa Liu, Alexandra Gangi, Yosef Nasseri, Katelyn Atkins, Karen Zaghiyan, Zuri Murrell, Arsen Osipov, Andrew Hendifar, Megan Hitchins, Jun Gong.

Jun Gong: ctDNA-guided adjuvant immunotherapy in stage III MSI-H dMMR colon cancer

More posts featuring Jun Gong.

Alexandra Gangi Andrew Hendifar Arsen Osipov cancer Colon cancer immunotherapy Jun Gong Karen Zaghiyan Katelyn Atkins Louisa Liu Megan Hitchins Nicholas Burley OncoDaily Oncology Yosef Nasseri Yurhee Lee Zuri Murrell

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage